OptimizeRx Co. (NASDAQ:OPRX) Stake Reduced by Blair William & Co. IL

Blair William & Co. IL trimmed its stake in OptimizeRx Co. (NASDAQ:OPRX) by 11.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 601,383 shares of the company’s stock after selling 75,711 shares during the quarter. Blair William & Co. IL owned approximately 3.26% of OptimizeRx worth $2,923,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Royce & Associates LP acquired a new stake in shares of OptimizeRx in the 4th quarter worth about $5,198,000. Bullseye Asset Management LLC increased its stake in shares of OptimizeRx by 55.6% in the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock valued at $1,652,000 after purchasing an additional 76,458 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of OptimizeRx by 670.3% during the fourth quarter. JPMorgan Chase & Co. now owns 59,952 shares of the company’s stock valued at $291,000 after buying an additional 52,169 shares during the last quarter. AMH Equity Ltd boosted its position in shares of OptimizeRx by 25.0% during the fourth quarter. AMH Equity Ltd now owns 125,000 shares of the company’s stock worth $608,000 after buying an additional 25,000 shares during the period. Finally, Greenwood Capital Associates LLC grew its holdings in OptimizeRx by 31.5% in the 4th quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company’s stock worth $431,000 after buying an additional 21,240 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on OPRX. JMP Securities reiterated a “market outperform” rating and set a $8.00 price target on shares of OptimizeRx in a research report on Thursday, February 6th. B. Riley raised shares of OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th. Lake Street Capital reissued a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a research note on Tuesday, December 24th. Stephens began coverage on shares of OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price target for the company. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 price objective (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and a consensus target price of $9.06.

Insider Activity

In related news, Director James Paul Lang bought 321,408 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were bought at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the transaction, the director now directly owns 389,452 shares of the company’s stock, valued at approximately $2,959,835.20. This trade represents a 472.35 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.10% of the company’s stock.

OptimizeRx Trading Up 0.2 %

Shares of NASDAQ:OPRX opened at $8.66 on Tuesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market capitalization of $160.12 million, a price-to-earnings ratio of -6.51 and a beta of 1.31. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $14.13. The company has a 50 day moving average price of $6.32 and a 200 day moving average price of $5.98.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.